Sections
| Title |
|---|
| Table Of Contents |
| 1 Introduction (Slide No. - 24) |
| 1.1 Objectives |
| 1.2 Markets Covered |
| 1.3 Stakeholders |
| 1.4 Market Size Estimation |
| 1.4.1 Market Definition |
| 1.4.2 Market Scope |
| 1.5 Research Methodology |
| 1.5.1 Secondary Research |
| 1.5.2 Primary Research |
| 1.5.3 Analysis & Output |
| 1.5.4 Assumptions |
| 1.5.5 Limitations |
| 1.5.6 Key Data Points Taken From Secondary Sources |
| 1.5.7 Key Data Points Taken From Primary Sources |
| 2 Executive Summary (Slide No. - 35) |
| 3 Market Dynamics (Slide No. - 41) |
| 3.1 Introduction |
| 3.2 Drivers |
| 3.2.1 Increasing Funding for New Stem Cell Lines |
| 3.2.2 Development of Advanced Genomic Methods for Stem Cell Analysis |
| 3.2.3 Increasing Focus on Human Embryonic Stem Cells |
| 3.2.4 Increasing Approvals of Clinical Trials for Stem Cells Therapy |
| 3.3 Restraints |
| 3.3.1 Lack of Required Infrastructures |
| 3.3.2 Difficulties Related With The Preservation of Stem Cells |
| 3.3.3 Ethical Issues Related to Embryonic Stem (ES) Cell |
| 3.3.4 Immunorejection After Stem Cell Transplantation |
| 3.3.5 Complexity Involved in Identification of Stem Cells in Adult Tissues |
| 3.4 Opportunities |
| 3.4.1 Lack of Effective Treatments to Cure Diseases |
| 3.4.2 Evolution of New Stem Cell Therapies |
| 3.4.3 Emergence of Induced Pluripotent Stem (IPS) Cells As An Alternative to Escs |
| 3.4.4 Emerging Markets Unfolds New Avenues Due to Low Regulatory Barriers and Clinical Trial Cost |
| 3.5 Challenges |
| 3.5.1 Dearth of Reimbursements |
| 3.5.2 High Costs Incurred in Stem Cell Processing |
| 3.5.3 Need of Automated Cell Culturing |
| 3.5.4 Lack of Clear Regulatory Guidelines |
| 3.6 Winning Imperatives |
| 3.6.1 Partnering With Academic Institutes |
| 3.6.2 Collaborating With Giant Pharmaceutical Firms |
| 3.6.3 High Focus on Emerging Markets |
| 3.7 Burning Issues |
| 3.7.1 Establishment of Safety Profiles |
| 3.7.2 Granting Orphan Drug Status to Stem Cell Therapeutics |
| 4 Pipeline Analysis (Slide No. - 56) |
| 5 Investor Network (Slide No. - 65) |
| 6 By Mode of Therapy (Slide No. - 70) |
| 6.1 Introduction |
| 6.2 Allogeneic Stem Cell Therapy Market, By Application |
| 6.2.1 Introduction |
| 6.2.2 Eye Diseases |
| 6.2.3 GIT Diseases |
| 6.2.4 Immune System Diseases |
| 6.2.5 Metabolic Diseases |
| 6.2.6 Musculoskeletal Disorders |
| 6.2.7 CNS Diseases |
| 6.2.8 CVS Diseases |
| 6.2.9 Wounds and Injuries |
| 6.2.10 Other Diseases |
| 6.3 Autologous Stem Cell Therapy Market, By Application |
| 6.3.1 Introduction |
| 6.3.2 GIT Diseases |
| 6.3.3 CNS Diseases |
| 6.3.4 Musculoskeletal Disorders |
| 6.3.5 Wounds and Injuries |
| 6.3.6 CVS Diseases |
| 6.3.7 Other Diseases |
| 7 By Therapeutic Applications (Slide No. - 94) |
| 7.1 Introduction |
| 7.2 Eye Diseases |
| 7.3 GIT Diseases |
| 7.4 Immune System Diseases |
| 7.5 Metabolic Diseases |
| 7.6 Musculoskeletal Disorders |
| 7.7 CNS Diseases |
| 7.8 CVS Diseases |
| 7.9 Wounds and Injuries |
| 7.10 Other Diseases |
| 8 Regulatory Landscape (Slide No. - 134) |
| 8.1 North America |
| 8.2 Asia-Pacific |
| 8.3 Europe |
| 8.4 ROW (Rest of The World) |
| 9 By Geography (Slide No. - 148) |
| 9.1 Introduction |
| 9.2 North America |
| 9.3 Europe |
| 9.4 Asia-Pacific |
| 9.5 ROW (Rest of The World) |
| 10 Competitive Landscape (Slide No. - 173) |
| 10.1 Overview |
| 10.2 Competitive Situation & Trends |
| 11 Company Profiles (Slide No. - 183) |
| 11.1 Aastrom Biosciences Inc. |
| 11.2 Advanced Cell Technologies, Inc. |
| 11.3 Athersys Inc. |
| 11.4 Celgene Corporation |
| 11.5 Cellular Dynamics International |
| 11.6 Cytori Therapeutics, Inc. |
| 11.7 Fibrocell Science, Inc. |
| 11.8 Gamida Cell Ltd. |
| 11.9 Mesoblast Ltd. |
| 11.10 Pluristem Therapeutics Inc. |
| 11.11 Stemcells Inc. |
| List of Tables (58 Tables) |
| Table 1 Global Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 2 Investor Network for Stem Cell Therapy Market: Private and Government Investments |
| Table 3 Investor Network Market: Private and Government Investments |
| Table 4 Investor Network Market: Government Investments |
| Table 5 Global Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 6 Global Market, By Geography, 2013-2020 ($Million) |
| Table 7 Global Allogeneic Stem Cell Therapy Market, By Application, 2013-2020 ($Million) |
| Table 8 Global Allogeneic Stem Cell Therapy Market, By Geography, 2013-2020 ($Million) |
| Table 9 Allogeneic Stem Cell Therapy Market for Eye Diseases, By Geography, 2013-2020 ($Million) |
| Table 10 Allogeneic Market for GIT Diseases, By Geography, 2013-2020 ($Million) |
| Table 11 Allogeneic Market for Immune System Diseases, By Geography, 2013-2020 ($Million) |
| Table 12 Allogeneic Market for Metabolic Diseases, By Geography, 2013-2020 ($Million) |
| Table 13 Allogeneic Market for Musculoskeletal Disorders , By Geography, 2013-2020 ($Million) |
| Table 14 Allogeneic Market for CNS Diseases, By Geography, 2013-2020 ($Million) |
| Table 15 Allogeneic Market for CVS Diseases, By Geography, 2013-2020 ($Million) |
| Table 16 Allogeneic Market for Wounds & Injuries, By Geography, 2013-2020 ($Million) |
| Table 17 Allogeneic Market for Other Diseases, By Geography, 2013-2020 ($Million) |
| Table 18 Global Autologous Stem Cell Therapy Market, By Application, 2013-2020 ($Million) |
| Table 19 Global Autologous Market, By Geography, 2013-2020 ($Million) |
| Table 20 Autologous Market for GIT Diseases, By Geography, 2013-2020 ($Million) |
| Table 21 Autologous Market for CNS Diseases, By Geography, 2013-2020 ($Million) |
| Table 22 Autologous Market for Musculoskeletal Disorders , By Geography, 2013-2020 ($Million) |
| Table 23 Autologous Market for Wounds & Injuries, By Geography, 2013-2020 ($Million) |
| Table 24 Autologous Market for CVS Diseases, By Geography, 2013-2020 ($Million) |
| Table 25 Autologous Market for Other Diseases, By Geography, 2013-2020 ($Million) |
| Table 26 Global Stem Cell Therapy Market, By Application, 2013-2020 ($Million) |
| Table 27 Stem Cell Therapy Market for Eye Diseases, By Geography, 2013-2020 ($Million) |
| Table 28 Market for GIT Diseases, By Geography, 2013-2020 ($Million) |
| Table 29 Market for Immune System Diseases, By Geography, 2013-2020 ($Million) |
| Table 30 Market for Metabolic Diseases, By Geography, 2013-2020 ($Million) |
| Table 31 Market for Musculoskeletal Disorders, By Geography, 2013-2020 ($Million) |
| Table 32 Market for CNS Diseases, By Geography, 2013-2020 ($Million) |
| Table 33 Market for CVS Diseases, By Geography, 2013-2020 ($Million) |
| Table 34 Market for Wounds & Injuries, By Geography, 2013-2020 ($Million) |
| Table 35 Market for Other Diseases, By Geography, 2013-2020 ($Million) |
| Table 36 Regulatory Landscape In U.S. - Fda Guidance Documents |
| Table 37 North America: Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 38 North America: Market, By Therapeutic Application, 2013-2020 ($Million) |
| Table 39 North America: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million) |
| Table 40 North America: Market, By Autologous Therapeutic Application, 2013-2020 ($Million) |
| Table 41 Europe: Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 42 Europe: Market, By Therapeutic Application, 2013-2020 ($Million) |
| Table 43 Europe: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million) |
| Table 44 Europe: Market, By Autologous Therapeutic Application, 2013-2020 ($Million) |
| Table 45 Asia-Pacific: Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 46 Asia-Pacific: Market, By Therapeutic Application, 2013-2020 ($Million) |
| Table 47 Asia-Pacific: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million) |
| Table 48 Asia-Pacific: Market, By Autologous Therapeutic Application, 2013-2020 ($Million) |
| Table 49 ROW: Market, By Mode of Therapy, 2013-2020 ($Million) |
| Table 50 ROW: Market, By Therapeutic Application, 2013-2020 ($Million) |
| Table 51 ROW: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million) |
| Table 52 ROW: Market, By Autologous Therapeutic Application, 2013-2020 ($Million) |
| Table 53 Product Approvals |
| Table 54 Partnerships, Collaborations, & Agreements |
| Table 55 Partnerships, Collaborations, & Agreements |
| Table 56 Acquisitions |
| Table 57 Patents |
| Table 58 Other Developments |
| List of Figures (32) |
| Figure 1 Market Segmentation, By Application |
| Figure 2 Market Segmentation, By Mode of Therapy |
| Figure 3 Pipeline Analysis, Based on Regulatory Authority, 2011-2013 |
| Figure 4 Pipeline Analysis, Based on Country, 2011-2013 |
| Figure 5 Pipeline Analysis, Based on Phase Under Clinical Trial, 2011-2013 |
| Figure 6 Pipeline Analysis, Based on No. of Patients Enrolled, 2011-2013 |
| Figure 7 Pipeline Analysis, Overall Therapy Based on Source of Cell Extraction, 2011-2013 |
| Figure 8 Pipeline Analysis, Allogeinic Therapy Based on Clinical Trial Phases, 2011-2013 |
| Figure 9 Pipeline Analysis, Autologous Therapy Based on Clinical Trial Phases, 2011-2013 |
| Figure 10 Pipeline Analysis, By Application, 2011-2013 |
| Figure 11 Pipeline Analysis, Allogeinic Therapy Based on Therapeutic Areas, 2011-2013 |
| Figure 12 Pipeline Analysis, Autologous Therapy Based on Therapeutic Areas, 2011-2013 |
| Figure 13 Overall Market: Based on Cell Lines Used, 2011-2013 |
| Figure 14 Allogeneic Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013 |
| Figure 15 Autologous Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013 |
| Figure 16 Pipeline Analysis of Stem Cell Therapy Market: Based on Major Companies, 2011-2013 |
| Figure 17 Investor Network for Stem Cell Therapy Market: Nih (U.S.) Funding |
| Figure 18 Market Segmentation, By Mode of Therapy |
| Figure 19 Comparison Between Allogeneic & Autologous Stem Cell Therapy Market |
| Figure 20 Estimated Cost Involved in The Manufacturing of Stem Cell Therapy Product |
| Figure 21 Allogeneic Stem Cell Therapy Market Segmentation, By Mode of Therapy |
| Figure 22 Autologous Stem Cell Therapy Market Segmentation, By Mode of Therapy |
| Figure 23 Market Segmentation, By Mode of Therapy |
| Figure 24 Stem Cell Therapy Process |
| Figure 25 Stem Cell Research Policies and Legislations |
| Figure 26 Geographic Distribution of CTG-Registered Stem Cell Therapy-Based Clinical Trials, 2000-2012 |
| Figure 27 Evolution of Stem Cell Research, North America |
| Figure 28 Evolution of Stem Cell Research, Europe |
| Figure 29 Evolution of Stem Cell Research, Asia-Pacific |
| Figure 30 Key Growth Strategies, 2010-2014 |
| Figure 31 Share of Key Companies in Patents Category, 2010-2014 |